Autophagy and SARS-CoV-2 infection: Apossible smart targeting of the autophagy pathway

Area of Science:

• Virology
• Cell Biology
• Nanomedicine

Background:

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes widespread illness and death.
• Betacoronaviruses, including SARS-CoV-2, are known to inhibit autophagy flux, leading to autophagosome accumulation.
• Existing FDA-approved drugs repurposed for SARS-CoV-2 treatment modulate the autophagy pathway.

Discussion:

• Repurposed drugs targeting autophagy may not directly antagonize the virus but rather suppress autophagy flux.
• This suppression could paradoxically lead to the activation of apoptosis in infected cells due to autophagosome accumulation.
• The cross-talk between autophagy and apoptosis suggests a novel therapeutic mechanism for controlling viral replication.

Key Insights:

• Over-accumulation of autophagosomes, induced by autophagy-suppressing drugs, may trigger apoptosis, leading to infected cell death.
• This apoptotic cell death could disrupt the SARS-CoV-2 replication cycle, presenting a potential treatment avenue.
• Current repurposed drug strategies face challenges due to severe off-target adverse effects.

Outlook:

• Nanoparticle-based drug delivery systems offer a promising approach to target autophagy specifically at infection sites.
• This targeted delivery could enhance therapeutic efficacy against SARS-CoV-2 while minimizing systemic toxicity.
• Further research into nanoparticle-mediated autophagy modulation is crucial for developing safer and more effective COVID-19 treatments.